Apricot extract inhibits the P-gp-mediated efflux of talinolol

Journal of Pharmaceutical Sciences

Volumn 91, Issue 12, 2002, Pages 2539-2548

  Deferme, Sven ^a   Mols, Raf ^a   Van Driessche, Willy ^b   Augustijns, Patrick ^a  

^a Laboratory for Pharmacotechnology   (Belgium)

^b Department of Physiology ^*  (Belgium)

Author keywords

Absorption enhancement; Apricot extract; Caco 2; In situ perfusion; P glycoprotein; Ussing chamber

Indexed keywords

APRICOT EXTRACT; GLYCOPROTEIN P; PLANT EXTRACT; TALINOLOL; UNCLASSIFIED DRUG; VERAPAMIL; PROPANOLAMINE DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; APRICOT; CELL STRAIN CACO 2; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG RETENTION; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE ABSORPTION; INTESTINE PERFUSION; MALE; MODEL; NONHUMAN; PH; POLARIZATION; RAT; REACTOR; ANIMAL; ARTICLE; DRUG ANTAGONISM; HUMAN; METABOLISM; PHYSIOLOGY; PRUNUS; WISTAR RAT;

ANIMALS; CACO-2 CELLS; HUMANS; INTESTINAL ABSORPTION; MALE; P-GLYCOPROTEIN; PLANT EXTRACTS; PROPANOLAMINES; PRUNUS; RATS; RATS, WISTAR;

EID: 0036892450     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10262     Document Type: Conference Paper

References (35)

1. Gottesman MM, Pastan I, Ambudkar SV. 1996. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 6:610-617.
2. Silverman JA. 1999. Multidrug-resistance transporters. Pharm Biotechnol 12:353-386.
3. Szabo D, Keyzer H, Kaiser HE, Molnar J. 2000. Reversal of multidrug resistance of tumor cells. Anticancer Res 20:4261-4274.
4. Fromm MF. 2000. P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 38:69-74.
5. Ushigome F, Takanaga H, Matsuo H, Yanai S, Tsukimori K, Nakano H, Uchiumi T, Nakamura T, Kuwano M, Ohtani H, Sawada Y. 2000. Human placental transport of vinblastine, vincristine, digoxine and progesterone: Contribution of P-glycoprotein. Eur J Pharmacol 408:1-10.
6. Wacher VJ, Salphati L, Benet LZ. 2001. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 46:89-102.
7. Suzuki H, Sugiyama Y. 2000. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur J Pharm Sci 12:3-12.
8. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR. 1999. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 16:408-414.
9. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. 1999. Biochemical, cellular, and pharmacological aspects of the multi-drug transporter. Annu Rev Pharmacol Toxicol 39:361-398.
10. Seelig A. 1998. A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 251:252-261.
11. Juliano R, Ling V. 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-162.
12. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. 1981. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967-1972.
13. Twentyman P, Bleehen N. 1991. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin. Eur J Cancer 7:1639-1642.
14. Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH. 1997. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 100:2430-2436.
15. Bardelmeijer HA, Beijnen JH, Brouwer KR, Rosing H, Nooijen WJ, Schellens JH, Van Tellingen O. 2000. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin Cancer Res 6:4416-4421.
16. Green LJ, Marder P, Slapak CA. 2001. Modulation by LY335979 of P-glycoprotein function in multi-drug-resistant cell lines and human natural killer cells. Biochem Pharmacol 61:1393-1396.
17. Krishna R, Mayer LD. 2000. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anti-cancer drugs. Eur J Pharm Sci 11:265-283.
18. Carver PL, Fleisher D, Zhou Y, Kaul D, Kazanjian P, Li C. 1999. Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients. Pharm Res 16:718-724.
19. Fleisher D, Cheng L, Zhou Y, Pao LH, Karim A. 1999. Drug, meal and formulation interactions influencing drug absorption after oral administration - Clinical implications. Clin Pharmacokinet 36:233-254.
20. Shimizu M. 1999. Modulation of intestinal functions by food substances. Nahrung 43:S154-S158.
21. Williams L, Davis JA, Lowenthal DT. 1993. The influence of food on the absorption and metabolism of drugs. Clin Nutr 77:815-829.
22. Ameer B, Weintraub RA. 1997. Drug interactions with grapefruit juice. Clin Pharmacokinet 33:103-121.
23. Plouzek CA, Ciolino HP, Clarke R, Yeh GC. 1999. Inhibition of P-glycoprotein activity and reversal of multidrug resistance in vitro by rosemary extract. Eur J Cancer 35:1541-1545.
24. Spahn-Langguth H, Langguth P. 2001. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur J Pharm Sci 12:361-367.
25. Takanaga H, Ohnishi A, Yamada S, Matsuo H, Morimoto S, Shoyama Y, Ohtani H, Sawada Y. 2000. Polymethoxylated flavones in orange juice are inhibitors of P-glycoprotein but not Cytochrome P450 3A4. J Pharmacol Exp Ther 293:230-236.
26. Deferme S, Van Gelder J, Augustijns P. in press. The inhibitory effect of fruit extracts on P-glycoprotein related efflux carriers: An in vitro screening. J Pharm Pharmacol, accepted for publication.
27. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB. 2002. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral bioavailability of fexofenadine. Clin Pharmacol Ther 71:11-20.
28. Mitsunaga Y, Takanaga H, Matsuo H, Naito M, Tsuruo T, Ohtani H, Sawada Y. 2000. Effect of bioflavanoids on vincristine transport across blood-brain barrier. Eur J Pharmacol 395:193-201.
29. Shapiro AB, Ling V. 1997. Effect of quercetin on Hoechst 3342 transport by purified and reconstituted P-glycoprotein. Biochem Pharmacol 53:587-596.
30. Hanafy A, Langguth P, Spahn-Langguth H. 2001. Pretreatment with potent P-glycoprotein ligands may increase intestinal secretion in rats. Pharm Res 12:405-415.
31. 1-adrenoceptor antagonist talinolol in man. Biopharm Drug Dispos 16:403-414.
32. Van Gelder J, Deferme S, Annaert P, Naesens L, De Clercq E, Van den Mooter G, Kinget R, Augustijns P. 2000. Increased absorption of the antiviral ester prodrug tenofovir disoproxil in rat ileum by inhibiting its intestinal metabolism. Drug Metab Dispos 28:1394-1396.
33. Becquemont L, Verstuyft C, Kerb R, Brinkmann U, Lebot M, Jaillon P, Funck-Brentano C. 2001. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther 70:311-316.
34. Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, Benet LZ. 1999. Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res 16:478-485.
35. Evers R, De Haas M, Sparidans R, Beijnen J, Wielinga PR, Lankelma J, Borst P. 2000. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer 83:375-383.